AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Asit, this week, competitor Novo Nordisk out with earnings and news that their blockbuster weight drug, Wegovy posted better ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

SINGAPORE - Media OutReach Newswire - 22 December 2023 - Novo Nordisk Pharma (Thailand) Ltd. has emerged triumphant by securing three prestigious accolades at the Asia Pacific Enterprise Awards (APEA) ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...